REMINDER: Our user survey closes on Friday, please submit your responses here.
You can always bet on a Simon Thomson recommendation that the share price will bomb the next day (sigh). Caught out again!
Looks like it is doing :-)
And, as usual, like the bad penny, the price drops.......
Spotted this article in IC today though re airport testing which may put a damper on expectations. (I used to have shares in this company but bailed out at a substantial loss so don't get too excited, Simon is always plugging it as it drops to recover his reputation, just kidding Simon):-
"Kromek has already developed a prototype to sample air and identify the presence of any biological pathogen – including Covid-19 or any mutant version that may emerge over time. The technology can be used to immediately flag the presence of someone with a contagious disease and allow effective mitigation of the risk of transmission. By placing samplers in high footfall areas, such as airports and hospitals, or where people are in close proximity for long periods, threats can be identified without having to individually test people. Knowing a carrier is infected with a disease before they infect further individuals is key to halting the onset of an outbreak and before it causes major global disruption. Non-military applications include use in shopping centres, sports arenas, theme parks, schools, hospitals, offices, airplanes, and cruise ships. Importantly, it’s incredibly accurate, giving a false alarm in just one in 800,000 tests.
Chief executive Arnab Basu revealed during this morning’s results call that Kromek will undertake field trials with the pre-production prototype collecting airborne samples from urban and rural locations starting in January, and has field tests scheduled in London with two UK government agencies: The Defence Science and Technology Laboratory (DSTL), an executive agency of the Ministry of Defence; and Defence Aviation Repair Agency (DARA). Kromek also plans for delivery of units for pilot deployment in the US in the first half of 2021."
Agree entirely with that comment. Rather dour Colin than some Slick Jim bull****ting his way through. My only concern with Omega is not the near future which is bright but how they manage the transition to a much larger business which is implied by all the 'jam tomorrow' messages. As a former consultant I've been involved helping to fix many businesses which have faltered during growth, usually issues with the quality of the original management team who may not possess the skillsets (e.g. project and process management) for a more complex organisation, communication and decision making system, IT scaling/knowledge (look at the laughable recent **** up in the NHS with someone using a 20 year old version of Excel to manage way too much data for a current example) and managing the change in organisation culture which always accompanies growth. Hopefully they are wise to this risk. For now I am happy to be invested here and hope that they succeed in their plans.
If history is anything to go by, a tip from dear old ST usually is followed a few days later by a large drop. Most of my worst dogs have been ST's strong buys at one time or another and then lost two thirds of their value. (pennant, stm, kromek, bp marsh, to name a few grand.)
Good news but limited impact on the price again I see. I could have broke even at 190 a couple of weeks back, nearly did and now wish I'd gotten out then as there seems to be no lower resistance point with this share which always drifts aimlessly downward after a surge.
Here we go again. Why is it lately that every time Simon Thompson (IC) puts out another update with a 'buy - undervalued' rating for one of his value stocks which have gone down the toilet, the share price bombs - it has done this with most of his recent updates on 1pm, Miton and Avingtrans to name but a few.
Long article but Simon is saying:- "The bottom line is that Jarvis's shares have been de-rated to a level at which the rising payout now provides very strong dividend support, and the rating is clearly far more appealing given the earnings multiple has contracted from 19 times to 12 times since I advised selling last year. Moreover, if the company can land the contract for the new automated wealth management service, then I would expect a decent share price re-rating as analysts upgrade their earnings forecasts, and significantly so for later years. Frankly, the downside risk looks limited and the upside from sealing the above contract, or for that matter any other awards in the pipeline, is effectively in the price for free. On a bid-offer spread of 300p to 305p, and offering 25 per cent upside to the lower end of my target price range between 375p and 400p, I rate Jarvis's shares a buy"
Anyone else not had anything yet? Supposed to be paid out by today.